The overall goal of the Imaging Core is to develop, implement, optimize, and validate quantitative surrogate biomarkers of tumor treatment response. This Core will be dedicated to providing scientific and technical resources and support for non-invasive imaging of small animal models of cancer in vivo] and is fundamental to the success of three of the four projects described in this application. Projects supported by the Imaging Core are directed at employing existing as well as novel, targeted therapies which will elicit molecular signatures that can be imaged via optical, SPECT, and PET methods and then complemented with the (downstream) physiological information obtained from ultrasound, MRI, and CT. In particular, Project 1 (PI: Arteaga) and Project 3 (PI: Pietenpol) will employ noninvasive molecular imaging metrics (FLT-PET, FDG-PET, Annexin-V microSPECT and optical) to assess tumor cell proliferation, glucose metabolism, and apoptosis in response to novel therapies. Project 2 (PI: Mundy) will employ noninvasive molecular imaging metrics (bioluminescence, fluorescence, and microSPECT/CT) to track breast cancer metastases to bone and assess bone quality. In addition to providing the methods required by SPORE projects, the Imaging Core will develop techniques that can augment these studies as well as support developmental pilot projects. The equipment and personnel needed to support research by investigators from within the SPORE will be provided by the Center for Small Animal Imaging (CSAI) (see Resources)). Funds obtained through the SPORE will support collaborations with expert imaging science faculty for the development and implementation of cutting edge imaging protocols;support for imaging system operators and technical staff who will handle animal preparation and monitoring as well as operate the instruments;support for data analysis and for quantitative image analysis customized to specific applications, including the coregistration and integration of multiple imaging modalities, histology and proteomics. 1. Provide non-invasive imaging metrics of tumor initiation, progression and treatment response to investigators in the Vanderbilt Breast SPORE. 2. Provide collaborations with expert imaging science faculty for the implementation of cutting edge imaging protocols to address each investigators goals. The Imaging Core will support experts in nuclear, optical, MRI, CT, and ultrasound imaging. 3. Provide support for data analysis and for quantitative image analysis customized to specific applications, including the co-registration and integration of multiple imaging modalities, histology and proteomics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098131-10
Application #
8376850
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2013-08-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
10
Fiscal Year
2012
Total Cost
$157,184
Indirect Cost
$54,507
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Mayer, Ingrid A; Abramson, Vandana G; Formisano, Luigi et al. (2016) A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res :
Lee, Taekyu; Bian, Zhiguo; Zhao, Bin et al. (2016) Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. FEBS Lett :
Harris, Leonard A; Frick, Peter L; Garbett, Shawn P et al. (2016) An unbiased metric of antiproliferative drug effect in vitro. Nat Methods 13:497-500
Zhao, Min; Kim, Pora; Mitra, Ramkrishna et al. (2016) TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res 44:D1023-31
Bhola, Neil E; Jansen, Valerie M; Koch, James P et al. (2016) Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res 76:440-52
Degnim, Amy C; Dupont, William D; Radisky, Derek C et al. (2016) Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer 122:2971-8
Zhao, Junfei; Cheng, Feixiong; Wang, Yuanyuan et al. (2016) Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach. Mol Cell Proteomics 15:642-56
Pelz, Nicholas F; Bian, Zhiguo; Zhao, Bin et al. (2016) Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. J Med Chem 59:2054-66
Jansen, Valerie M; Mayer, Ingrid A; Arteaga, Carlos L (2016) Is There a Future for AKT Inhibitors in the Treatment of Cancer? Clin Cancer Res 22:2599-601
Hassanein, Mohamed; Hight, Matthew R; Buck, Jason R et al. (2016) Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18:18-23

Showing the most recent 10 out of 304 publications